Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://stephenv086fhh2.blogripley.com/profile